Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liprotamase - Alkira Therapeutics

Next Previous
X
Search
Drug Profile

Liprotamase - Alkira Therapeutics

Alternative Names: ALTU-135; Liprotamase; LY-3031642; Sollpura; TheraCLEC™-Total; Trizytek™

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics
  • Developer Anthera Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics
  • Class Amylases; Carboxylic ester hydrolases; Pancreatic enzymes; Peptide hydrolases
  • Mechanism of Action Amylase replacements; Lipase replacements; Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Exocrine pancreatic insufficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Exocrine pancreatic insufficiency

Most Recent Events

  • 28 Mar 2018 Anthera Pharmaceuticals has 4 European patents and 16 non-European issued patents for liprotamase
  • 12 Mar 2018 Discontinued - Phase-III for Exocrine pancreatic insufficiency (In adolescents, In children, In infants, In adults) in USA (PO) (NCT02823964)
  • 12 Mar 2018 Discontinued - Phase-III for Exocrine pancreatic insufficiency (In adolescents, In children, In the elderly, In adults) in USA, United Kingdom, Spain, Poland, Lithuania, Israel, Hungary (PO) (NCT03051490)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top